Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775768 | 1.00 | FAAH (0.48) | FAAHGHSRTRPV1CYP3A4CYP2C19 | |
| SCHEMBL3071576 | 0.98 | FAAH (0.51) | FAAHGHSRTRPV1CYP3A4CYP2C19 | |
| SCHEMBL3071572 | 0.98 | FAAH (0.51) | FAAHGHSRTRPV1CYP3A4CYP2C19 | |
| SCHEMBL772183 | 0.86 | GHSR (0.46) | FAAHGHSRTRPV1CYP3A4ALDH1A1 | |
| SCHEMBL2156573 | 0.84 | GHSR (0.46) | FAAHGHSRTRPV1CYP3A4CYP2C19 | |
| SCHEMBL5065679 | 0.84 | GHSR (0.46) | FAAHGHSRTRPV1CYP3A4CYP2C19 | |
| SCHEMBL13476046 | 0.83 | CYP3A4 (0.49) | FAAHTRPV1CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL25384603 | 0.83 | FAAH (0.62) | FAAHGHSRTRPV1ALDH1A1HPGD | |
| SCHEMBL27658921 | 0.83 | FAAH (0.49) | FAAHGHSRTRPV1CYP3A4CYP2C19 | |
| SCHEMBL16512496 | 0.82 | FAAH (0.53) | FAAHGHSRTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | FAAH 3682/4885GHSR 4302/4885TRPV1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.